2.
患者特征与无进展生存期和总生存期
Patient characteristics and survival
| Characteristics | n | Median PFS (month) |
χ2 | P | Median OS (month) |
χ2 | P | |
| PFS: progression-free survival; OS: overall survival. | ||||||||
| Chemotherapy | 2nd line/3nd line and above | 55/136 | 3.1/2.2 | 0.255 | 0.614 | 18.3/14.4 | 0.263 | 0.608 |
| Non-platinum/Platinum | 80/111 | 2.0/3.1 | 11.708 | 0.001 | 12.2/19.2 | 5.682 | 0.017 | |
| Non-pemetrexed/Pemetrexed | 94/97 | 2.1/3.1 | 1.647 | 0.199 | 13.3/16.3 | 1.476 | 0.224 | |
| Response to chemotherapy | Non-PR/PR | 181/10 | 2.3/10.1 | 6.309 | 0.012 | 14.2/18.5 | 1.635 | 0.201 |
| EGFR-TKIs resistance | Primary resistance/Acquired resistance | 51/140 | 2.9/2.8 | 0.001 | 0.975 | 11.2/16.3 | 2.046 | 0.153 |
| EGFR-TKIs acquired resistance | Dramtic progression/Gradual and local progression | 52/88 | 2.1/3.7 | 2.246 | 0.134 | 12.3/17.5 | 0.017 | 0.433 |
| Non-platinum-based/ Platinum-based |
58/82 | 2.0/3.1 | 9.689 | 0.002 | 14.23/19.33 | 4.286 | 0.038 | |
| Dramtic progression | Non-platinum-based/ Platinum-based |
26/26 | 1.5/3.0 | 11.026 | 0.001 | 11.2/19.2 | 6.033 | 0.014 |